S Nimkar1, C Valvi2, D Kadam2, B B Rewari3, A Kinikar2, N Gupte1,4, N Suryavanshi1, A Deluca1,4,5, A Shankar5, J Golub4,5, R Bollinger4, A Gupta1,4,5, I Marbaniang1, V Mave1,4. 1. Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India. 2. Byramjee Jeejeebhoy Government Medical College, Pune, India. 3. National AIDS Control Organization, New Delhi, India. 4. Johns Hopkins University School of Medicine, Baltimore, MD, USA. 5. Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Abstract
OBJECTIVES: India has the highest number of HIV-infected adolescents in Asia, but little is known about their treatment outcomes. We assessed rates and factors associated with loss to follow-up (LTFU) and mortality among Indian adolescents. METHODS: The analysis included adolescents (10-19 years old) starting antiretroviral therapy (ART) between 2005 and 2014 at BJ Government Medical College, Pune, India. LTFU was defined as missing more than three consecutive monthly visits. The competing-risks method was used to calculate subdistribution hazard ratios (SHRs) of predictors for LTFU, with death as the competing risk. Cox proportional hazard models were used to identify predictors of mortality. RESULTS: Of 717 adolescents starting ART, 402 with complete data were included in the analysis. Of these, 61% were male and 80% were perinatally infected, and the median baseline CD4 count was 174 cells/μL. LTFU and mortality rates were 4.4 and 4.9/100-person years, respectively. Cumulative LTFU incidence increased from 6% to 15% over 6 years. Age ≥ 15 years [adjusted SHR (aSHR) 2.44; 95% confidence interval (CI) 1.18-5.02] was a risk factor for LTFU. Cumulative mortality increased from 9.5% to 17.9% over 6 years. World Health Organization (WHO) stages III and IV [adjusted hazard ratio (aHR) 2.26; 95% CI: 1.14-4.48] and an increase in CD4 count by 100 cells/μL (aHR: 0.59; 95% CI: 0.43-0.83) were associated with mortality. CONCLUSIONS: A third of adolescents had been lost to follow-up or died by follow-up year 6. Older age was a risk factor for LTFU and advanced clinical disease for death. Strategies to improve retention counselling for older adolescents and closer clinical monitoring of all adolescents must be considered.
OBJECTIVES: India has the highest number of HIV-infected adolescents in Asia, but little is known about their treatment outcomes. We assessed rates and factors associated with loss to follow-up (LTFU) and mortality among Indian adolescents. METHODS: The analysis included adolescents (10-19 years old) starting antiretroviral therapy (ART) between 2005 and 2014 at BJ Government Medical College, Pune, India. LTFU was defined as missing more than three consecutive monthly visits. The competing-risks method was used to calculate subdistribution hazard ratios (SHRs) of predictors for LTFU, with death as the competing risk. Cox proportional hazard models were used to identify predictors of mortality. RESULTS: Of 717 adolescents starting ART, 402 with complete data were included in the analysis. Of these, 61% were male and 80% were perinatally infected, and the median baseline CD4 count was 174 cells/μL. LTFU and mortality rates were 4.4 and 4.9/100-person years, respectively. Cumulative LTFU incidence increased from 6% to 15% over 6 years. Age ≥ 15 years [adjusted SHR (aSHR) 2.44; 95% confidence interval (CI) 1.18-5.02] was a risk factor for LTFU. Cumulative mortality increased from 9.5% to 17.9% over 6 years. World Health Organization (WHO) stages III and IV [adjusted hazard ratio (aHR) 2.26; 95% CI: 1.14-4.48] and an increase in CD4 count by 100 cells/μL (aHR: 0.59; 95% CI: 0.43-0.83) were associated with mortality. CONCLUSIONS: A third of adolescents had been lost to follow-up or died by follow-up year 6. Older age was a risk factor for LTFU and advanced clinical disease for death. Strategies to improve retention counselling for older adolescents and closer clinical monitoring of all adolescents must be considered.
Authors: Celestin Bakanda; Josephine Birungi; Robert Mwesigwa; Jean B Nachega; Keith Chan; Alexis Palmer; Nathan Ford; Edward J Mills Journal: PLoS One Date: 2011-04-29 Impact factor: 3.240
Authors: Mweete D Nglazi; Katharina Kranzer; Pearl Holele; Richard Kaplan; Daniella Mark; Heather Jaspan; Stephen D Lawn; Robin Wood; Linda-Gail Bekker Journal: BMC Infect Dis Date: 2012-01-25 Impact factor: 3.090
Authors: Ingrid T Katz; Annemarie E Ryu; Afiachukwu G Onuegbu; Christina Psaros; Sheri D Weiser; David R Bangsberg; Alexander C Tsai Journal: J Int AIDS Soc Date: 2013-11-13 Impact factor: 5.396
Authors: Azar Kariminia; Matthew Law; Mary-Ann Davies; Michael Vinikoor; Kara Wools-Kaloustian; Valeriane Leroy; Andrew Edmonds; Catherine McGowan; Rachel Vreeman; Lee Fairlie; Samuel Ayaya; Marcel Yotebieng; Elom Takassi; Jorge Pinto; Adebola Adedimeji; Karen Malateste; Daisy M Machado; Martina Penazzato; Rohan Hazra; Annette H Sohn Journal: J Int AIDS Soc Date: 2018-12 Impact factor: 5.396
Authors: Rodrick R Kisenge; Chris A Rees; Jacqueline M Lauer; Enju Liu; Wafaie W Fawzi; Karim P Manji; Christopher P Duggan Journal: Trop Med Health Date: 2020-06-04